CW Advisors LLC Buys 26,009 Shares of Novartis AG $NVS

CW Advisors LLC boosted its position in Novartis AG (NYSE:NVS) by 52.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,340 shares of the company’s stock after acquiring an additional 26,009 shares during the quarter. CW Advisors LLC’s holdings in Novartis were worth $9,117,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. GFG Capital LLC bought a new position in shares of Novartis during the 2nd quarter valued at about $26,000. WPG Advisers LLC purchased a new stake in Novartis in the first quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new position in Novartis during the second quarter valued at approximately $30,000. Barrett & Company Inc. purchased a new position in shares of Novartis during the second quarter worth approximately $31,000. Finally, MCF Advisors LLC lifted its holdings in shares of Novartis by 66.0% in the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company’s stock worth $32,000 after acquiring an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 1.0%

NVS opened at $132.36 on Friday. Novartis AG has a one year low of $96.06 and a one year high of $134.24. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.88 and a quick ratio of 0.68. The business has a 50 day simple moving average of $129.03 and a two-hundred day simple moving average of $123.18. The firm has a market capitalization of $279.60 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 1.89 and a beta of 0.52.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.26 by ($0.01). The business had revenue of $14.36 billion for the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. Novartis’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm posted $2.06 earnings per share. Analysts predict that Novartis AG will post 8.45 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on NVS. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Tuesday. The Goldman Sachs Group reaffirmed a “sell” rating and set a $118.00 price objective (down from $119.00) on shares of Novartis in a research note on Friday, September 12th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Jefferies Financial Group restated a “hold” rating on shares of Novartis in a research report on Monday, October 27th. Finally, HC Wainwright cut Novartis to a “neutral” rating in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novartis presently has an average rating of “Hold” and an average target price of $122.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.